A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors

The COVID-19 pandemic caused by SARS-CoV-2 has created an unprecedented global health emergency. As of July 2021, only three antiviral therapies have been approved by the FDA for treating infected patients, highlighting the urgent need for more antiviral drugs. The SARS-CoV-2 3CL protease (3CLpro) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vankadara, Subramanyam, Wong, Yun Xuan, Liu, Boping, See, Yi Yang, Tan, Li Hong, Tan, Qian Wen, Wang, Gang, Karuna, Ratna, Guo, Xue, Tan, Shu Ting, Fong, Jia Yi, Joy, Joma, Chia, C.S. Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277557/
https://www.ncbi.nlm.nih.gov/pubmed/34271072
http://dx.doi.org/10.1016/j.bmcl.2021.128263

Ejemplares similares

Ejemplares similares